Real-world treatment patterns and clinical outcomes in patients with prostate cancer.

References

1. 1.↵
   1. Sung H,
   2. Ferlay J,
   3. Siegel RL,
   4. Laversanne M,
   5. Soerjomataram I,
   6. Jemal A, et al.

   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Shore ND,
   2. Ionescu-Ittu R,
   3. Laliberté F,
   4. Yang L,
   5. Lejeune D,
   6. Yu L, et al.

   Beyond frontline therapy with abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: a real-world US study. Clin Genitourin Cancer 2021; 19: 480–490.

   OpenUrl
3. 3.↵
   1. Almutairi AA,
   2. Edali AM,
   3. Khan SA,
   4. Aldihan WA,
   5. Alkhenizan AH

   . Yield of prostate cancer screening at a community based clinic in Saudi Arabia. Saudi Med J 2019; 40: 681–686.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Hamdy FC,
   2. Donovan JL,
   3. Lane JA,
   4. Metcalfe C,
   5. Davis M,
   6. Turner EL, et al.

   Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023; 388: 1547–1558.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Prashar J,
   2. Schartau P,
   3. Murray E

   . Supportive care needs of men with prostate cancer: a systematic review update. Eur J Cancer Care (Engl) 2022; 31: e13541.

   OpenUrl
6. 6.↵
   1. Rawla P

   . Epidemiology of prostate cancer. World J Oncol 2019; 10: 63–89.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Choi JB,
   2. Myong JP,
   3. Lee Y,
   4. Kim I,
   5. Kim JH,
   6. Hong SH, et al.

   Does increased body mass index lead to elevated prostate cancer risk? It depends on waist circumference. BMC Cancer 2020; 20: 589.

   OpenUrl
8. 8.↵
   1. Nishimoto M,
   2. Fujita K,
   3. Yamamoto Y,
   4. Hashimoto M,
   5. Adomi S,
   6. Banno E, et al.

   Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer. Transl Cancer Res 2022; 11: 2681–2687.

   OpenUrl
9. 9.↵
   1. Bonn SE,
   2. Barnett MJ,
   3. Thornquist M,
   4. Goodman G,
   5. Neuhouser ML

   . Body mass index and prostate cancer risk in the carotene and retinol efficacy trial. Eur J Cancer Prev 2019; 28: 212–219.

   OpenUrl
10. 10.↵
    1. Chen WJ,
    2. Kong DM,
    3. Li L

    . Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review. Asian J Androl 2021; 23: 163–169.

    OpenUrl
11. 11.↵
    1. Lehtonen M,
    2. Heiskanen L,
    3. Reinikainen P,
    4. Kellokumpu-Lehtinen PL

    . Both comorbidity and worse performance status are associated with poorer overall survival after external beam radiotherapy for prostate cancer. BMC Cancer 2020; 20: 324.

    OpenUrl
12. 12.↵
    1. Bubendorf L,
    2. Schöpfer A,
    3. Wagner U,
    4. Sauter G,
    5. Moch H,
    6. Willi N, et al.

    Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578–583.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Freedland SJ,
    2. Davis M,
    3. Epstein AJ,
    4. Arondekar B,
    5. Ivanova JI

    . Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer (mCRPC) in the US medicare population. Prostate Cancer Prostatic Dis 2024; 27: 327–333.

    OpenUrl